2023
DOI: 10.1080/14737175.2023.2239500
|View full text |Cite
|
Sign up to set email alerts
|

Long-term central nervous system (CNS) consequences of COVID-19 in children

Saskia Howe de la Torre,
Valeria Parlatini,
Samuele Cortese
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 147 publications
0
6
0
Order By: Relevance
“…The correlation between TLR4 dimerization and activation with pathogenicity of the SARS-CoV-2 variants indicate TLR4 as a potential therapeutic target for treatment of COVID-19. While so far there are no FDA approved TLR4 antagonists available, intensive research [106] on TLR4 as a therapeutic target is ongoing, with emphasis on respiratory and neurological complications of SARS-CoV-2 [107], also with respect to accumulating data for long-term nervous system consequences after COVID-19 [108,109]. Beside various TLR4 antagonists which inhibit binding to or dimerization of TLR4, also inhibitors of the downstream signaling pathways, including inhibitors of the NF-κB pathway, are promising targets for therapeutic intervention [50,51].…”
Section: Discussionmentioning
confidence: 99%
“…The correlation between TLR4 dimerization and activation with pathogenicity of the SARS-CoV-2 variants indicate TLR4 as a potential therapeutic target for treatment of COVID-19. While so far there are no FDA approved TLR4 antagonists available, intensive research [106] on TLR4 as a therapeutic target is ongoing, with emphasis on respiratory and neurological complications of SARS-CoV-2 [107], also with respect to accumulating data for long-term nervous system consequences after COVID-19 [108,109]. Beside various TLR4 antagonists which inhibit binding to or dimerization of TLR4, also inhibitors of the downstream signaling pathways, including inhibitors of the NF-κB pathway, are promising targets for therapeutic intervention [50,51].…”
Section: Discussionmentioning
confidence: 99%
“…As for adults, CNS dysfunction seems to persist for a long time in a significant portion of infected pediatric patients, resulting in so-called Long COVID-19 [1,5,6,38,39]. Headache, fatigue, 'brain fog' and memory impairment, anosmia or ageusia, and dizziness are the most frequent symptoms associated with Long COVID-19, with a highly variable prevalence among the studies [1,5,6,40].…”
Section: Discussionmentioning
confidence: 99%
“…Neuropsychiatric symptoms are also described in patients with Long COVID-19, especially mood symptoms and anxiety, affecting their daily functioning and well-being [6,8,41]. The direct effects of the virus are not the sole contributors, as pandemic-related psychosocial factors have also influenced this group of patients in an unclear manner.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations